Ludmila Cavalcante
Constant myeloid leukaemia (CML) is characterised by a BCR-ABL1 combination quality of proportional chromosomal mobility, which indicates the presence of a clonal myeloproliferative threat. CML is a rare disease that affects children and teens, with a predicted annual frequency of 2.5 cases per million in children and young adults. It accounts for 2-3% of all instances of childhood leukaemia and 9% of cases of leukaemia in teenagers between the ages of 15 and 19. Tyrosine kinase inhibitor (TKI) therapy is the standard of care for individuals with CML, and it is only possible to stop TKI therapy in a small percentage of patients. Patients with CML now have significantly more endurance thanks to the introduction of TKIs. Long-term TKI treatment is required for CML children, and routine immunizations have been hindered by the lack of knowledge regarding TKI safety. In this report, we provide a summary of the effects of TKIs on the emergence of resistance and its implications for immunizations.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 